Glial reactivity in resistance to methamphetamine-induced neurotoxicity

Journal of Neurochemistry

Volumn 125, Issue 4, 2013, Pages 566-574

  Friend, Danielle M ^a   Keefe, Kristen A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

astrocyte; dopamine; methamphetamine; microglia; toxicity

Indexed keywords

CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CELL TYPE; CONTROLLED STUDY; GLIA CELL; HYPERTHERMIA; MALE; MICROGLIA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; STRIATE CORTEX;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIGENS, CD11B; ASTROCYTES; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; FEVER; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; METHAMPHETAMINE; MICROGLIA; NEUROTOXICITY SYNDROMES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 84876805044     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12201     Document Type: Article

References (50)

1. Abbott N. J., Ronnback L., and, Hansson E., (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53.
2. Anderson C. M., and, Swanson R. A., (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32, 1-14.
3. Borges K., Gearing M., McDermott D. L., Smith A. B., Almonte A. G., Wainer B. H., and, Dingledine R., (2003) Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp. Neurol. 182, 21-34.
4. Bowyer J. F., and, Ali S., (2006) High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60, 521-532.
5. Bowyer J. F., Davies D. L., Schmued L., Broening H. W., Newport G. D., Slikker W. Jr., and, Holson R. R., (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268, 1571-1580.
6. Callaghan R. C., Cunningham J. K., Sajeev G., and, Kish S. J., (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov. Disord. 25, 2333-2339.
7. Callaghan R. C., Cunningham J. K., Sykes J., and, Kish S. J., (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 120, 35-40.
8. Cappon G. D., Morford L. L., and, Vorhees C. V., (1997) Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Brain Res. Dev. Brain Res. 103, 155-162.
9. Chen Y., Vartiainen N. E., Ying W., Chan P. H., Koistinaho J., and, Swanson R. A., (2001) Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J. Neurochem. 77, 1601-1610.
10. Crofts N., Hopper J. L., Milner R., Breschkin A. M., Bowden D. S., and, Locarnini S. A., (1994) Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV. Eur. J. Epidemiol. 10, 687-694.
11. Ellis R. J., Childers M. E., Cherner M., Lazzaretto D., Letendre S., and, Grant I., and Group H. I. V. N. R. C. (2003) Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J. Infect. Dis. 188, 1820-1826.
12. Fleckenstein A. E., Metzger R. R., Wilkins D. G., Gibb J. W., and, Hanson G. R., (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 282, 834-838.
13. Friend D. M., Son J. H., Keefe K. A., and, Fricks-Gleason A. N., (2013) Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity. J. Pharmacol. Exp. Ther. 344, 511-521.
14. Gross N. B., Duncker P. C., and, Marshall J. F., (2011) Cortical ionotropic glutamate receptor antagonism protects against methamphetamine- induced striatal neurotoxicity. Neuroscience 199, 272-283.
15. Guilarte T. R., Nihei M. K., McGlothan J. L., and, Howard A. S., (2003) Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122, 499-513.
16. Halpin L. E., and, Yamamoto B. K., (2012) Peripheral ammonia as a mediator of methamphetamine neurotoxicity. J. Neurosci. 32, 13155-13163.
17. Hanisch U. K., (2002) Microglia as a source and target of cytokines. Glia 40, 140-155.
18. Hanson J. E., Birdsall E., Seferian K. S., Crosby M. A., Keefe K. A., Gibb J. W., Hanson G. R., and, Fleckenstein A. E., (2009) Methamphetamine- induced dopaminergic deficits and refractoriness to subsequent treatment. Eur. J. Pharmacol. 607, 68-73.
19. Harris N. V., Thiede H., McGough J. P., and, Gordon D., (1993) Risk factors for HIV infection among injection drug users: results of blinded surveys in drug treatment centers, King County, Washington 1988-1991. J. Acquir. Immune Defic. Syndr. 6, 1275-1282.
20. Harvey D. C., Lacan G., Tanious S. P., and, Melega W. P., (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 871, 259-270.
21. Hozumi I., Aquino D. A., and, Norton W. T., (1990) GFAP mRNA levels following stab wounds in rat brain. Brain Res. 534, 291-294.
22. Kaul M., and, Lipton S. A., (1999) Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl Acad. Sci. USA 96, 8212-8216.
23. Kitamura O., Takeichi T., Wang E. L., Tokunaga I., Ishigami A., and, Kubo S., (2010) Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg. Med. 12, 57-62.
24. Kogan F. J., Nichols W. K., and, Gibb J. W., (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36, 363-371.
25. Kreutzberg G. W., (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312-318.
26. LaVoie M. J., Card J. P., and, Hastings T. G., (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 187, 47-57.
27. Maragos W. F., Young K. L., Turchan J. T., Guseva M., Pauly J. R., Nath A., and, Cass W. A., (2002) Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J. Neurochem. 83, 955-963.
28. Mark K. A., Soghomonian J. J., and, Yamamoto B. K., (2004) High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 24, 11449-11456.
29. McCann U. D., Wong D. F., Yokoi F., Villemagne V., Dannals R. F., and, Ricaurte G. A., (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18, 8417-8422.
30. Min K. J., Yang M. S., Kim S. U., Jou I., and, Joe E. H., (2006) Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J. Neurosci. 26, 1880-1887.
31. Nash J. F., and, Yamamoto B. K., (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581, 237-243.
32. O'Callaghan J. P., and, Miller D. B., (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751.
33. O'Dell S. J., Weihmuller F. B., and, Marshall J. F., (1992) MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow. Ann. N. Y. Acad. Sci. 648, 317-319.
34. Okada S., Nakamura M., Katoh H., et al,. (2006) Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat. Med. 12, 829-834.
35. Ramirez S. H., Potula R., Fan S., et al,. (2009) Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J. Cereb. Blood Flow Metab. 29, 1933-1945.
36. Sekine Y., Ouchi Y., Sugihara G., et al,. (2008) Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28, 5756-5761.
37. Shah A., Silverstein P. S., Kumar S., Singh D. P., and, Kumar A., (2012a) Synergistic cooperation between methamphetamine and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. PLoS ONE 7, e52060.
38. Shah A., Silverstein P. S., Singh D. P., and, Kumar A., (2012b) Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-kappaB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J. Neuroinflammation 9, 52.
39. Sharma H. S., and, Kiyatkin E. A., (2009) Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J. Chem. Neuroanat. 37, 18-32.
40. Shih A. Y., Johnson D. A., Wong G., Kraft A. D., Jiang L., Erb H., Johnson J. A., and, Murphy T. H., (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 23, 3394-3406.
41. Sofroniew M. V., (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638-647.
42. Sofroniew M. V., and, Vinters H. V., (2010) Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35.
43. Sonsalla P. K., Nicklas W. J., and, Heikkila R. E., (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
44. Sriram K., Miller D. B., and, O'Callaghan J. P., (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 96, 706-718.
45. Thomas D. M., and, Kuhn D. M., (2005) Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J. Neurochem. 92, 790-797.
46. Thomas D. M., Walker P. D., Benjamins J. A., Geddes T. J., and, Kuhn D. M., (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311, 1-7.
47. Wagner G. C., Ricaurte G. A., Seiden L. S., Schuster C. R., Miller R. J., and, Westley J., (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151-160.
48. Zhang Z. G., Bower L., Zhang R. L., Chen S., Windham J. P., and, Chopp M., (1999) Three-dimensional measurement of cerebral microvascular plasma perfusion, glial fibrillary acidic protein and microtubule associated protein-2 immunoreactivity after embolic stroke in rats: a double fluorescent labeled laser-scanning confocal microscopic study. Brain Res. 844, 55-66.
49. Zhao M. L., Kim M. O., Morgello S., and, Lee S. C., (2001) Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J. Neuroimmunol. 115, 182-191.
50. Zhu J. P., Xu W., Angulo N., and, Angulo J. A., (2006) Methamphetamine-induced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration. Neurotoxicology 27, 131-136.